Gemcitabine + Cisplatin + Durvalumab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extrahepatic Cholangiocarcinoma
Conditions
Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA
Trial Timeline
Aug 23, 2024 → Apr 1, 2028
NCT ID
NCT06440993About Gemcitabine + Cisplatin + Durvalumab
Gemcitabine + Cisplatin + Durvalumab is a phase 2 stage product being developed by AstraZeneca for Extrahepatic Cholangiocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06440993. Target conditions include Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06440993 | Phase 2 | Recruiting |
| NCT05655949 | Phase 2 | Recruiting |
Competing Products
4 competing products in Extrahepatic Cholangiocarcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| cisplatin + gemcitabine hydrochloride | Eli Lilly | Phase 3 | 77 |
| exatecan mesylate | Daiichi Sankyo | Phase 2 | 52 |
| aprepitant + gemcitabine hydrochloride + capecitabine + fluorouracil | Merck | Phase 2 | 52 |
| Gemcitabine + Cisplatin + Sorafenib | Bayer | Phase 2 | 49 |